SARS-CoV-2 Epitopes Are Recognized by a Public and Diverse Repertoire of Human T Cell Receptors

Understanding the determinants of adaptive immune response to SARS-CoV-2 is critical for fighting the ongoing COVID-19 pandemic. Here we assayed both antibody and T-cell reactivity to SARS-CoV-2 antigens in COVID-19 convalescent patients and healthy donors sampled before and during the pandemic. Our results show that while anti-SARS-CoV-2 antibodies can distinguish convalescent patients from healthy donors, the magnitude of T-cell response was more pronounced in healthy donors sampled during COVID-19 pandemic than in donors sampled before the outbreak. This hints at the possibility that some individuals have encountered the virus but were protected by T-cell cross-reactivity observed. A public and diverse T-cell response was observed for two A*02-restricted SARS-CoV-2 epitopes, revealing a set of T-cell receptor motifs displaying germline-encoded features. Bulk CD4+ and CD8+ T-cell response to SARS-CoV-2 glycoprotein S is characterized by multiple groups of homologous T-cell receptor sequences some of which are shared across multiple donors, indicating the existence of immunodominant epitopes. Overall, our findings indicate that T cells form an efficient response to SARS-CoV-2 and alongside the antibodies can serve as a useful biomarker for surveying SARS-CoV-2 exposure and immunity. We hope that data, including the set of specific T-cell receptors identified in this study can serve as a basis for future developments of SARS-CoV-2 vaccinations and monitoring.

[1]  Ludmila V. Danilova,et al.  The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity , 2018, Cancer Immunology Research.

[2]  C. Cunningham-Rundles,et al.  A serological assay to detect SARS-CoV-2 seroconversion in humans , 2020, Nature Medicine.

[3]  Richard Molenkamp,et al.  Phenotype of SARS-CoV-2-specific T-cells in COVID-19 patients with acute respiratory distress syndrome , 2020, medRxiv.

[4]  Jincun Zhao,et al.  T Cell Responses Are Required for Protection from Clinical Disease and for Virus Clearance in Severe Acute Respiratory Syndrome Coronavirus-Infected Mice , 2010, Journal of Virology.

[5]  Mikhail Shugay,et al.  Exploring the pre-immune landscape of antigen-specific T cells , 2018, Genome Medicine.

[6]  G. Gao,et al.  Screening and Identification of Severe Acute Respiratory Syndrome-Associated Coronavirus-Specific CTL Epitopes1 , 2006, The Journal of Immunology.

[7]  G. Gao,et al.  Detection of mobile colistin resistance gene mcr-9 in carbapenem-resistant Klebsiella pneumoniae strains of human origin in Europe. , 2019, The Journal of infection.

[8]  M. Radosevich,et al.  Treatment of severe acute respiratory syndrome with convalescent plasma. , 2003, Hong Kong medical journal = Xianggang yi xue za zhi.

[9]  Florian Krammer,et al.  Serology assays to manage COVID-19 , 2020, Science.

[10]  G. Barlow,et al.  Novel coronavirus disease (Covid-19): The first two patients in the UK with person to person transmission , 2020, Journal of Infection.

[11]  Jun Yuan,et al.  Antibody responses to SARS-CoV-2 in patients with COVID-19 , 2020, Nature Medicine.

[12]  Bjoern Peters,et al.  Quantitating T Cell Cross-Reactivity for Unrelated Peptide Antigens1 , 2009, The Journal of Immunology.

[13]  Lei Liu,et al.  The landscape of lung bronchoalveolar immune cells in COVID-19 revealed by single-cell RNA sequencing , 2020, medRxiv.

[14]  L. Gostin,et al.  The Novel Coronavirus Originating in Wuhan, China: Challenges for Global Health Governance. , 2020, JAMA.

[15]  Jincun Zhao,et al.  Virus-Specific Memory CD8 T Cells Provide Substantial Protection from Lethal Severe Acute Respiratory Syndrome Coronavirus Infection , 2014, Journal of Virology.

[16]  J. Xie,et al.  Significant Changes of Peripheral T Lymphocyte Subsets in Patients with Severe Acute Respiratory Syndrome , 2004, The Journal of infectious diseases.

[17]  R. Koup,et al.  Long-lived effector/central memory T-cell responses to severe acute respiratory syndrome coronavirus (SARS-CoV) S antigen in recovered SARS patients , 2006, Clinical Immunology.

[18]  Steven Y. C. Tong,et al.  Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19 , 2020, Nature Medicine.

[19]  Andrew K. Sewell,et al.  VDJdb in 2019: database extension, new analysis infrastructure and a T-cell receptor motif compendium , 2019, Nucleic Acids Res..

[20]  D. Speiser,et al.  T cell receptor alpha variable 12‐2 bias in the immunodominant response to Yellow fever virus , 2017, European journal of immunology.

[21]  R. Scheuermann,et al.  A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2 , 2020, Cell Host & Microbe.

[22]  S. Bose,et al.  Immunoinformatics‐aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019‐nCoV , 2020, Journal of medical virology.

[23]  R. Koup,et al.  Persistent memory CD4+ and CD8+ T-cell responses in recovered severe acute respiratory syndrome (SARS) patients to SARS coronavirus M antigen. , 2007, The Journal of general virology.

[24]  Frank Grosveld,et al.  A human monoclonal antibody blocking SARS-CoV-2 infection , 2020, Nature Communications.

[25]  D. Cummings,et al.  A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease , 2020, medRxiv.

[26]  Richard A. Olshen,et al.  Diversity and clonal selection in the human T-cell repertoire , 2014, Proceedings of the National Academy of Sciences.

[27]  Y. Wen,et al.  Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications , 2020, medRxiv.

[28]  Morten Nielsen,et al.  NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data , 2020, Nucleic Acids Res..

[29]  T. Schumacher,et al.  Generation of peptide–MHC class I complexes through UV-mediated ligand exchange , 2006, Nature Protocols.

[30]  Kai Zhao,et al.  A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.

[31]  Chuan Qin,et al.  Reinfection could not occur in SARS-CoV-2 infected rhesus macaques , 2020 .

[32]  Chloe H. Lee,et al.  In silico identification of vaccine targets for 2019-nCoV , 2020, F1000Research.

[33]  Weifeng Chen,et al.  T-Cell Epitopes in Severe Acute Respiratory Syndrome (SARS) Coronavirus Spike Protein Elicit a Specific T-Cell Immune Response in Patients Who Recover from SARS , 2004, Journal of Virology.

[34]  J. Greenbaum,et al.  Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.

[35]  B. Ni,et al.  Identification of a novel conserved HLA-A*0201-restricted epitope from the spike protein of SARS-CoV , 2009, BMC Immunology.

[36]  Qi Jin,et al.  Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19) , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  Ali Danesh,et al.  Human immunopathogenesis of severe acute respiratory syndrome (SARS) , 2007, Virus Research.

[38]  Y. Wen,et al.  Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications , 2020, medRxiv.

[39]  Yuan Shi,et al.  Convalescent plasma as a potential therapy for COVID-19 , 2020, The Lancet Infectious Diseases.

[40]  Yong-tang Zheng,et al.  Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients , 2020, Cellular & Molecular Immunology.

[41]  Amalio Telenti,et al.  Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody , 2020, Nature.

[42]  D. Burton,et al.  Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model , 2020, bioRxiv.

[43]  E. Mariotti-Ferrandiz,et al.  High-resolution repertoire analysis reveals a major bystander activation of Tfh and Tfr cells , 2018, Proceedings of the National Academy of Sciences.

[44]  O. Lund,et al.  The role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained from improved predictions of proteasomal cleavage , 2005, Immunogenetics.

[45]  Meriem Bensouda Koraichi,et al.  Longitudinal high-throughput TCR repertoire profiling reveals the dynamics of T-cell memory formation after mild COVID-19 infection , 2020, bioRxiv.

[46]  Xinquan Wang,et al.  Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals , 2020, Immunity.

[47]  T. Schumacher,et al.  Conditional MHC class I ligands and peptide exchange technology for the human MHC gene products HLA-A1, -A3, -A11, and -B7 , 2008, Proceedings of the National Academy of Sciences.

[48]  Sean K. Maden,et al.  Human leukocyte antigen susceptibility map for SARS-CoV-2 , 2020, medRxiv.

[49]  U. Reimer,et al.  Presence of SARS-CoV-2 reactive T cells in COVID-19 patients and healthy donors , 2020, medRxiv.

[50]  Dmitrii S Shcherbinin,et al.  Comprehensive analysis of structural and sequencing data reveals almost unconstrained chain pairing in TCRαβ complex , 2019, bioRxiv.

[51]  E. Holmes,et al.  A new coronavirus associated with human respiratory disease in China , 2020, Nature.

[52]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[53]  Ruifu Yang,et al.  Identification of an HLA-A*0201–restricted CD8+ T-cell epitope SSp-1 of SARS-CoV spike protein , 2004, Blood.

[54]  Anastasiia L. Sycheva,et al.  Tracking T-cell immune reconstitution after TCRαβ/CD19-depleted hematopoietic cells transplantation in children , 2017, Leukemia.

[55]  Christopher D. Paddock,et al.  Cellular Immune Responses to Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Infection in Senescent BALB/c Mice: CD4+ T Cells Are Important in Control of SARS-CoV Infection , 2009, Journal of Virology.

[56]  P. Wang,et al.  Characterization of anti-viral immunity in recovered individuals infected by SARS-CoV-2 , 2020, medRxiv.

[58]  W. Phoolcharoen,et al.  Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). , 2020, Asian Pacific journal of allergy and immunology.

[59]  R. Koup,et al.  Characterization of SARS-CoV-specific memory T cells from recovered individuals 4 years after infection , 2009, Archives of Virology.

[60]  A. McMichael,et al.  T Cell Responses to Whole SARS Coronavirus in Humans1 , 2008, The Journal of Immunology.